Document:

Document

Exhibit 10.1

RETIREMENT AGREEMENT

    This AGREEMENT (the “Agreement”) is made and entered into on the 30th day of December, 2021, by and between ERIE INDEMNITY COMPANY, a Pennsylvania corporation with its principal place of business in Erie, Pennsylvania (the “Company”), and ROBERT C. INGRAM III, residing in Erie, Pennsylvania (the “Executive”).

RECITALS:

A.    The Executive announced to the Company in June 2021 that he planned to retire from the Company at the close of 2021.

B.    The Board of Directors appreciates and respects the leadership provided by the Executive, the talent development he supported, the multitude of contributions he made, the relationships he fostered, and the Company’s business, technological and financial performance during his career with the Company.

C.    The Board desires that, following his retirement, the Executive assist with the transition of his role as Executive Vice President and Chief Information Officer of the Company to his successor as further described in this Agreement, and the Executive is willing to do so.  

D.    The Company and the Executive agree that it is in their respective best interests to make certain provisions related to the Executive's retirement from the Company.

NOW, THEREFORE, in consideration of the premises and mutual covenants contained in this Agreement, and intending to be legally bound, the Company and the Executive agree as follows:

1.Effective Date.  This Agreement will become effective only if it is fully executed on or before December 31, 2021, and, if it is fully executed on or before that date, the date of execution will be the “Effective Date” of the Agreement. 
2.Officer Status; Retirement.  
a.The Executive shall retire from the Company and step down from his positions as Executive Vice President and Chief Information Officer of the Company effective on December 31, 2021, at 11:59 p.m. (EST).  The Executive shall also retire and step down from his positions as a director, officer, and employee of each Affiliated Company (as defined below), effective at the same time.  
b.For the purposes of this Agreement and the Release, “Affiliated Company” will refer to each of the following: Erie Insurance Exchange and each entity that is a subsidiary or affiliated company of the Company or of Erie Insurance Exchange.  

3.Consideration.

a.In consideration of the execution and performance of this Agreement by the Executive, and subject to the remaining provisions of this Section 3 and to Sections 4, 5, 6, 7, 8 and 10, the Executive will receive from the Company the following payments, which include payments to which the Executive would not otherwise be entitled:
(i) With respect to the Company's Annual Incentive Plan (“AIP”) and the award made to the Executive for the 2021 performance period under the AIP:

(A)   In accordance with the terms of the AIP, for the 2021 performance period, the Executive Compensation and Development Committee of the Board of Directors of the Company (the “Committee”): (1) will measure the Company’s performance for the performance period against the performance goals set out in the Executive’s award agreement for the performance period and will calculate the Company incentive award earned by the Executive for the performance period (or, if applicable, that would have been earned by the Executive for the performance period had the Executive remained employed through the last day of the performance period), based on the Company’s achievement of the applicable performance goals (the “earned Company incentive award” for the performance period), and (2) will calculate the amount of the Executive’s target award based on his individual performance goals for the 2021 performance period (the “target individual incentive award” for the performance period).  
(B)  If the Committee exercises its discretion to reduce or eliminate Company incentive awards that would otherwise have been earned by executive officers as a class under the AIP for the 2021 performance period, the Committee may reduce the Executive’s earned Company incentive award for the performance period by a percentage reduction that is not more than the average of the percentage reductions applied to the Company incentive awards of the executive officers.  
(C)  The Executive will have a vested interest of 100 percent in his earned Company incentive and target individual incentive awards for the 2021 performance period.  The earned Company incentive award taken into account in calculating the Executive’s vested interest will be after any reduction imposed under paragraph (B).
(D)  The Company shall pay to the Executive his vested interest in his earned Company incentive and target individual incentive awards for the 2021 performance period at the time provided under the AIP, which will be no later than December 31, 2022. 
(E)  The amount paid to the Executive under paragraph (D) will be reduced in accordance with the Executive’s deferral election under the Company’s Deferred Compensation Plan. 
(F)  The Committee's determination of the amount of award to be paid shall be in accordance with the terms of the AIP and shall be final and binding on all interested parties.
(ii)  With respect to the Company's Long Term Incentive Plan (“LTIP”) and the awards made to the Executive for the 2019-2021, 2020-2022, and 2021-2023 performance periods under the LTIP:  
(A)  In accordance with the terms of the LTIP, for the 2019-2021, 2020-2022, and 2021-2023 performance periods, the Committee shall measure the Company’s performance for the performance period against the performance goals set out in the Executive’s award agreement for the performance period and shall calculate the award earned by the Executive for the performance period (or, if applicable, that would have been earned by the Executive for the performance period had the Executive remained employed through the last day of the performance period), based on the Company’s achievement of the applicable performance goals (the “earned award” for the performance period). 
2

(B)  If the Committee exercises its discretion to reduce or eliminate awards that would otherwise have been earned by executive officers as a class under the LTIP for the 2019-2021 performance period, the Committee may reduce the Executive’s earned award for that performance period by a percentage reduction that is not more than the average of the percentage reductions applied to the awards of the executive officers for that performance period.  The Committee shall not reduce the Executive’s earned award for either the 2020-2022 or the 2021-2023 performance period.
(C)  The Executive will have a vested interest of 100 percent in his earned award for the 2019-2021 performance period, a vested interest of 66 2/3 percent in his earned award for the 2020-2022 performance period, and a vested interest of 33 1/3 percent in his earned award for the 2021-2023 performance period.  The earned award taken into account in calculating the Executive’s vested interest for the 2019-2021 performance period will be after any reduction imposed under paragraph (B).
(D)  Subject to any deferrals as more fully described in (G) below, the Company shall pay to the Executive his vested interest in his earned award for the 2019-2021 performance period in 2022 at the time provided in the LTIP, which will be no later than December 31, 2022.  
(E)  Subject to any deferrals as more fully described in (G) below, the Company shall pay to the Executive his vested interest in his earned award for the 2020-2022 performance period no later than December 31, 2022.  
(F)  Subject to any deferrals as more fully described in (G) below, the Company shall pay to the Executive his vested interest in his earned award for the 2021-2023 performance period no later than December 31, 2022.  
(G)  The amounts paid to the Executive under paragraphs (D), (E) and (F) will be reduced in accordance with the Executive’s applicable deferral election under the Company’s Incentive Compensation Deferral Plan.
(H)  The Committee's determination of the amount of award to be paid shall be in accordance with the terms of the LTIP and shall be final and binding on all interested parties.
(iii)  The Company shall also reimburse the Executive for any legal fees and related expenses he incurs in connection with his entry into this Agreement, provided however that the reimbursement shall not exceed, in the aggregate, $5,000 (five thousand dollars), and provided further that the Executive provides the Company with reasonable substantiating documentation by November 30 of the calendar year following the calendar year in which such fees and expenses were incurred.  The Company shall pay the amount to be reimbursed under this paragraph within thirty days after receipt of such documentation.
b.If the Executive dies before payment of a benefit described in Section 3(a) to which the Executive is otherwise entitled under this Agreement, the Company shall pay the benefit at the scheduled time to the beneficiary or beneficiaries designated by the Executive from time to time in accordance with the terms of the AIP or LTIP, as applicable; provided, however, that if the Executive has not designated a beneficiary in accordance with the terms of the relevant plan, or if no designated beneficiary with respect to the plan survives the Executive, the Company shall pay the benefit to the default beneficiary indicated in the relevant plan.
3

c.Payments under this Section 3 will be subject to applicable deductions.  For the purposes of this Agreement, “applicable deductions” will mean any federal, state, or local taxes reasonably determined by the Company to be required to be withheld from amounts paid to the Executive pursuant to this Agreement.
d.Except as provided in this Agreement, the Executive agrees that he is not entitled to any other compensation (including, but not limited to, salary or bonuses), perquisites, or benefits of any kind or description from the Company, or from or under any employee benefit plan or fringe benefit plan sponsored by the Company, other than as described above and other than (i) his regular salary through his retirement date of December 31, 2021; (ii) payment for his unpaid vacation time, which will be computed in accordance with the Company’s past practices for departing employees and paid as soon as administratively practical after the termination of his employment; (iii) his accrued benefits under the Erie Insurance Group Retirement Plan for Employees; (iv) his accrued benefits under the Erie Insurance Group Employee Savings Plan; (v) his accrued benefit under the Supplemental Executive Retirement Plan for Certain Members of the Erie Insurance Group Retirement Plan for Employees (“SERP”); (vi) any benefit the Executive may have accrued under the Company’s Deferred Compensation Plan; (vii) any benefit the Executive may have accrued under the Company’s Incentive Compensation Deferral Plan; (viii) any rights the Executive may have under COBRA on account of the termination of his employment; and (ix), with respect to any of the capacities in which the Executive served the Company or an Affiliated Company, and with respect to any service of the Executive as a fiduciary or trustee of any employee benefit plans or trusts or other trusts maintained or sponsored by the Company or an Affiliated Company, any rights the Executive may have for indemnity in relation to any acts or omissions of the Executive or a claim for coverage under any applicable insurances, or any claim relating to enforcement of the Agreement.  
e.The parties acknowledge and agree that the Executive is not releasing any rights he may have as an owner or holder of the Company’s common stock or any rights he has to enforce this Agreement.  In addition, the Executive is not releasing any rights that he has to be indemnified (including any right to reimbursement of expenses) arising under applicable law, the certificate of incorporation or bylaws (or similar constituent documents of the Company), any indemnification agreement between him and the Company (including, without limitation, the Indemnification Agreement entered into on August 13, 2012), or any directors’ and officers’ or other liability insurance policy of the Company.  Furthermore, the Company agrees to provide indemnification to the Executive, in the same manner and to the same extent as the highest-level officers of the Company, through the Ongoing Cooperation Period (as defined below) and for any claim that may arise relating to or arising out of any matters occurring through the Ongoing Cooperation Period, and for a period of at least three years after the Ongoing Cooperation Period.
4.Executive's Waiver and Release.  

a.After the termination of the Executive’s employment with the Company, the Executive shall execute a waiver and release in the form attached as Exhibit A to this Agreement (the “Release”).  Notwithstanding any provision of this Agreement to the contrary, the payments described in Section 3(a)(ii)(E) and (F) (referring to payments related to the 2020-2022 and 2021-2023 LTIP performance periods) will not be paid unless the Executive executes the Release by January 21, 2022, and the seven-day revocation period described in the Release expires with no revocation.  The rest of this Agreement will remain in full force and effect.  

b.The Executive represents and warrants that the Release and a proposed form of agreement was first presented to him for his consideration before the Effective Date and that the Company has encouraged and advised the Executive in writing, prior to his signing this Agreement, to consult with an attorney of the Executive's choosing concerning all of the terms of this Agreement and the Release.

4

c.The Company represents and warrants that, as of the date of this Agreement, it does not have knowledge of any claim or action against the Executive.

5.Non-Disparagement.  Subject to Section 6(b) below, the Executive shall not disparage the Company or its officers, directors, or employees in any way orally or in writing, and the directors and executive and senior officers of the Company shall likewise not disparage the Executive, provided, however, that nothing in this Section will prohibit: (a) the Executive or the Company from disclosing truthful information if required by law (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process); or (b) either party from acting in good faith to enforce the party’s rights under this Agreement. 

6.Covenants as to Confidential Information and Competition.  The Executive acknowledges and agrees as follows:  (i) this Section 6 is necessary for the protection of the legitimate business interests of the Company, (ii) the restrictions contained in this Section 6 with regard to geographical scope, length of term and types of restricted activities are reasonable; (iii) the Executive has received adequate and valuable consideration for entering into this Agreement, and (iv) the Executive's expertise and capabilities are such that his obligations under and the enforcement of this Section 6 by injunction or otherwise will not adversely affect the Executive's ability to earn a livelihood.

a.Confidentiality of Information and Nondisclosure.  The Executive agrees that the Executive shall not, directly or indirectly, without the express written approval of the Company, unless directed by applicable legal authority (including any court of competent jurisdiction, governmental agency having supervisory authority over the business of the Company or an Affiliated Company, or any legislative or administrative body having supervisory authority over the business of the Company or an Affiliated Company) having jurisdiction over the Executive, disclose to or use, or knowingly permit to be so disclosed or used, for the benefit of himself, any person, corporation or other entity other than the Company, (i) any non-public information concerning any financial matters, customer relationships, competitive status, supplier matters, internal organizational matters, current or future plans, or other business affairs of or relating to the Company or an Affiliated Company, (ii) any proprietary management, operational, trade, technical or other secrets or any other proprietary information or other data of the Company or an Affiliated Company, or (iii) any other information related to the Company or an Affiliated Company, or which the Executive should reasonably believe will be damaging to the Company or an Affiliated Company, which has not been published and is not generally known outside of the Company.  The Executive acknowledges that all of the foregoing constitutes confidential and proprietary information, which is the exclusive property of the Company.  

b.Nothing in this Agreement or any other agreement with the Company prohibits or prevents the Executive from filing a complaint or charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before any federal, state, or local government agency.  Notwithstanding the non-disclosure, non-disparagement, or any other provision of this Agreement, the Executive acknowledges and affirms his understanding that nothing in this Agreement is intended to preclude, prohibit, or otherwise limit, in any way, his rights and abilities to contact, communicate with, or report matters to any government entity or agency including but not limited to the United States Department of Justice, any Office of Inspector General of any United States agency, the United States Securities and Exchange Commission, or Congress, regarding possible violations of laws or regulations; provided, Executive agrees not to disclose confidential information subject to a legal privilege of the Company, including but not limited to the attorney-client privilege and attorney work product doctrine.  However, to the maximum extent permitted by law, the Executive agrees that if such an administrative claim is made, the Executive shall not be entitled to recover any individual monetary relief or other individual remedies, except that this provision is not applicable to any bounty that may be recoverable by the Executive as a result of participating in the Securities and Exchange Commission’s whistleblower program. 
5

c.Legal Proceedings.    If the Executive is required by court order, subpoena or other legal process to disclose Confidential Information, the Executive shall immediately notify the Company of the requirement, in writing or via electronic mail at the following address, and shall give the Company a reasonable opportunity to respond before the Executive takes any action, or makes any decisions, in connection with the requirement:  Brian W. Bolash, Senior Vice President, Secretary and General Counsel, Erie Insurance Group, 100 Erie Insurance Place, P.O. Box 1699, Erie, PA 16530-0001, brian.bolash@erieinsurance.com. 

d.Restrictive Covenants.  For the period beginning January 1, 2022 through June 30, 2022 (the "Restrictive Period"), the Executive shall not directly or indirectly, on behalf of himself or in conjunction with any other individual or entity, own (other than less than 3 percent ownership in a publicly traded company), manage, operate, control,  participate in the ownership, management, operation, or control of, or render service in any capacity to, (i) any entity that offers property insurance, casualty insurance, or life insurance, or any combination of those products, and that operates in any of the states or territories in which the Company or an Affiliated Company is licensed and does business at the Effective Date or the date of the termination of the Executive's employment with the Company or (ii) any parent, subsidiary, or affiliate of such an entity.  The covenant in the preceding sentence does not apply to any state or territory in which the only Affiliated Company licensed and doing business is Erie Resource Management Corp., nor does the covenant apply to a parent, subsidiary, or affiliate of an entity described in clause (i) which parent, subsidiary, or affiliate itself does not offer property, casualty, or life insurance and does not manage or otherwise participate in the operation of any entity that offers property, casualty, or life insurance.  The Executive Compensation and Development Committee of the Board of Directors may, in its discretion, grant a waiver of this covenant, upon a written request by the Executive in advance of a proposed activity providing full disclosure of the nature of the proposed activity. The Executive further agrees that at no time during the Restrictive Period will the Executive attempt directly or indirectly to solicit or hire employees of the Company or any of its Affiliated Companies or to induce any of them to terminate their employment with the Company or any of its Affiliated Companies.  If these restrictions are adjudicated to be unreasonable in any legal proceeding, the parties agree to the reformation of these restrictions by the relevant court or tribunal to limits adjudicated to be reasonable, and the parties further agree that neither party may assert that these restrictions should be eliminated in their entirety by any court or tribunal.  If the Executive violates any of the provisions contained in this Section 6, the Restrictive Period shall be increased by the period of time from the commencement by the Executive of any violation until such violation has been cured to the satisfaction of the Company or enjoined by a court of competent jurisdiction.  

7.Company Property, Records, Files and Equipment.  By December 31, 2021, the Executive shall return all Company property he then has in his possession or control, including but not limited to all equipment, confidential information, records, and files, regardless of format or storage location. 

8.Breach of Agreement.  The Executive agrees that if he breaches any of the terms of this Agreement, the Company may pursue whatever rights it has under this Agreement, whether in law or in equity, without affecting the validity and enforceability of the Release contemplated by Section 4 of this Agreement. The Executive agrees that any breach of this Agreement may result in immediate and irreparable harm to the Company, and that the Company may not be reasonably or adequately compensated by damages in an action at law. The Executive agrees that if he breaches Section 6 of this Agreement, the Company will be entitled, to the extent permitted by law, immediately to cease to pay or provide the Executive or the Executive's dependents any compensation or benefit being, or to be, paid or provided pursuant to this Agreement, and also to obtain immediate injunctive relief restraining the Executive from conduct in breach of this Agreement.  In addition, the Executive agrees that if he breaches Section 6 of this Agreement, the Executive shall reimburse the Company and its Affiliated Companies for their costs and expenses (including, without limitation, all reasonable fees and expenses, including the costs of any computer forensics imaging and analysis, etc., as well as 
6

reasonable attorney’s fees) incurred by the Company and its Affiliated Companies in connection with the breach.  The Executive agrees that the incurrence of such fees and expenses will be necessary for the Company’s and its Affiliated Companies’ protection of its valuable confidential information, trade secrets, and business relationships.  Nothing in this Agreement shall be construed as prohibiting the Company from pursuing any other remedies available to it for a breach of this Agreement, including the recovery of damages from the Executive.

9.Notice of Immunity from Liability for Confidential Disclosure of a Trade Secret to the Government or in a Court Filing.  Notwithstanding the foregoing, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.   If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, a trade secret may be disclosed to his attorney and used in the court proceeding, if the Executive (c) files any document containing the trade secret under seal; and (d) does not disclose the trade secret, except pursuant to court order.

10.Ongoing Cooperation.  For the period from the date of the termination of the Executive’s employment with the Company through December 31, 2022 (the “Ongoing Cooperation Period”), the Executive agrees to use his reasonable efforts to assist, advise and cooperate with the Company if the Company so requests on issues that arose or were in any way developing during his employment with the Company.  The Executive shall furnish such assistance, advice or cooperation to the Company as the Company may reasonably request and as is within the Executive's reasonable capability.  Such assistance, advice and cooperation may include, but will not be limited to, assisting with the onboarding of, and appropriate transfer of knowledge to, the Company’s new Chief Information Officer, and the preparation for, or the conduct of, any litigation, investigation or proceeding involving matters or events which occurred during the Executive's employment by the Company as to which the Executive's knowledge or testimony may be important to the Company.  In connection with the preparation for, or the conduct of such litigation, investigation or proceeding as described in the preceding sentence, the Executive shall promptly provide the Company with any records or other materials in his possession that the Company may request in connection with the defense or prosecution of such litigation, investigation or proceeding.  The Company and the Executive anticipate that the level of cooperation services to be provided by the Executive is less than 20 percent of the Executive’s average level of services for the 36-month period ending December 31, 2021.  The Executive will not be entitled to any additional compensation for providing the cooperation, but the Company shall pay or reimburse the Executive for (i) his reasonable legal fees and expenses incurred in the course of providing such cooperation, provided that the Company agrees that the Executive’s engagement of his own counsel is necessary and appropriate, and (ii) his travel expenses reasonably incurred in the course of providing such cooperation, provided that the Executive provides reasonable substantiating documentation by November 30 of the calendar year following the calendar year in which the fee or expense was incurred; the Company shall make any payment required under this sentence within thirty days after receipt of such documentation.

11.Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania applicable to contracts executed in and to be performed in that commonwealth without regard to its conflicts of laws provisions.  Each of the parties irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the Commonwealth of Pennsylvania located in the County of Erie, Pennsylvania, and of the United States for the Western District of Pennsylvania for any litigation arising out of or relating to this Agreement or the transactions contemplated by this Agreement.  Any legal action relating to this Agreement shall be brought in the courts of the Commonwealth of Pennsylvania located in the County of Erie, Pennsylvania, and of the United States for the Western District of Pennsylvania and the parties irrevocably and unconditionally waive and will 
7

not plead or claim in any such court that venue is improper or that such litigation has been brought in an inconvenient forum. 

12.Waiver.  The waiver by a party of any breach by the other party of any provision of this Agreement will not operate or be construed as a waiver of any other or subsequent breach by a party.

13.Assignment.  This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company and the Company shall be obligated to require any successor to expressly acknowledge and assume its obligations under this Agreement.  This Agreement will inure to the extent provided under this Agreement to the benefit of and be enforceable by the Executive or the Executive's legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  The Executive may not delegate any of the Executive's duties, responsibilities, obligations or positions under this Agreement to any person and any such purported delegation will be void and of no force and effect.

14.Severability.  Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

15.Notices.  Any notices required or permitted to be given under this Agreement will be sufficient if in writing, and if personally delivered or when sent by first class certified or registered mail, postage prepaid, return receipt requested − in the case of the Executive, to his principal residence address, and in the case of the Company, to the address of its principal place of business as set forth above, to the attention of the General Counsel of the Company.

16.Entire Agreement.  This Agreement constitutes the entire agreement of the parties relating to the subject matter of this Agreement and supersedes any obligations of the Company under any previous agreements or arrangements, except as otherwise provided in this Agreement.  This Agreement does not supersede the Company’s Policy Regarding the Recoupment of Officer Bonuses in Certain Instances, as adopted on December 9, 2008, and as it may be amended.  The provisions of this Agreement may not be amended, modified, repealed, waived, extended or discharged except by an agreement in writing signed by the party against whom enforcement of any amendment, modification, repeal, waiver, extension or discharge is sought.  

17.Code Section 409A.  It is intended that this Agreement comply with the provisions of section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury regulations relating thereto (“Code Section 409A”), or an exemption to Code Section 409A.  Payments, rights and benefits may only be made, satisfied or provided under this Agreement upon an event and in a manner permitted by Code Section 409A, to the extent applicable, so as not to subject the Executive to the payment of taxes and interest under Code Section 409A.  In furtherance of this intent, this Agreement shall be interpreted, operated and administered in a manner consistent with these intentions, and to the extent that any regulations or other guidance issued under Code Section 409A would result in the Executive being subject to payment of additional income taxes or interest under Code Section 409A, the parties agree, to the extent possible, to amend this Agreement to maintain to the maximum extent practicable the original intent of this Agreement while avoiding the application of such taxes or interest under Code Section 409A.   All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation from service” as defined under Code Section 409A.  Notwithstanding any provision of this Agreement to the contrary, if, on the date of the Executive's separation from service, the Executive is a “specified employee” as defined under Code Section 409A, then, except to the extent that this Agreement does not provide for a “deferral of compensation” within the meaning of Code Section 409A of the Code, no payments may be made and no benefits may be provided to the Executive during the period beginning on the date of the Executive's separation from service and ending on the last day of the sixth month 
8

after such date.  In no event may the Executive, directly or indirectly, designate the calendar year of any payment under this Agreement.

18.Headings.  The descriptive headings used in this Agreement are used for convenience of reference only and do not constitute a part of this Agreement. 

19.Counterparts.  This Agreement may be executed in separate counterparts, both of which taken together shall constitute one and the same Agreement, and will be fully executed when one or more counterparts have been signed by and delivered to each party.
 
    
    THE EXECUTIVE EXPRESSLY WARRANTS AND REPRESENTS THAT, BEFORE ENTERING INTO THIS AGREEMENT, HE HAS RECEIVED A REASONABLE PERIOD OF TIME WITHIN WHICH TO CONSIDER ALL OF THE PROVISIONS CONTAINED IN THIS AGREEMENT AND THE RELEASE, THAT HE HAS FULLY READ, INFORMED HIMSELF OF AND UNDERSTANDS ALL THE TERMS, CONTENTS, CONDITIONS AND EFFECTS OF ALL PROVISIONS OF THIS AGREEMENT AND THE RELEASE, AND THAT HE CONSIDERS ALL SUCH PROVISIONS TO BE SATISFACTORY. 

    THE EXECUTIVE FURTHER EXPRESSLY WARRANTS AND REPRESENTS THAT NO PROMISE OR REPRESENTATION OF ANY KIND HAS BEEN MADE, EXCEPT THOSE EXPRESSLY STATED IN THIS AGREEMENT. 

    THE EXECUTIVE FURTHER EXPRESSLY WARRANTS AND REPRESENTS THAT THE COMPANY HAS ENCOURAGED AND ADVISED HIM IN WRITING, PRIOR TO HIS SIGNING THIS AGREEMENT, TO CONSULT WITH AN ATTORNEY OF THE EXECUTIVE’S CHOOSING CONCERNING ALL OF THE TERMS OF THIS AGREEMENT AND THE RELEASE.    

    THE EXECUTIVE FURTHER EXPRESSLY WARRANTS AND REPRESENTS THAT HE ENTERS INTO THIS AGREEMENT KNOWINGLY AND VOLUNTARILY.

    
IN WITNESS WHEREOF, the Executive and the Company, by its duly authorized representative, have signed this Agreement on the date set forth above.

												
	WITNESS:		THE EXECUTIVE:	
				
	/s/ W. Jeff Booth		/s/ Robert C. Ingram, III	
			      Robert C. Ingram, III	
			30 DEC 21	
				
			THE COMPANY:	
	ATTEST:		ERIE INDEMNITY COMPANY	
				
	/s/ Karen A. Skarupski		By: /s/ Brian W. Bolash
	
			    Brian W. Bolash	
			    Senior Vice President	
				

9Document

EXHIBIT 10.1

CONSULTING SERVICES AGREEMENT

This Consulting Services Agreement (this “Agreement”) is effective January 1, 2022 (the “Effective Date”) by and between Travere Therapeutics, Inc., 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (“Travere”) and Noah Rosenberg, M.D (“Consultant”).
    
    WHEREAS, Travere is engaged in research, development and commercialization of human pharmaceutical products for rare diseases;

    WHEREAS, Consultant is formerly the Chief Medical Officer of Travere;

    WHEREAS, Travere wishes to engage Consultant to provide the services set forth below on the terms and conditions set forth herein and the Consultant wishes to be so retained.

    NOW THEREFORE, in consideration of the promises and of the mutual covenants, conditions and agreements contained herein, the parties agree as follows:

ARTICLE ONE
CONSULTING SERVICES

1.1    Engagement.  Travere hereby agrees to engage Consultant to provide transitional consulting services to Travere  and to provide support with respect to regulatory submissions and related activities, as requested from time to time by Travere and as more specifically set forth in Exhibit A hereof (the “Services”) for the benefit of Travere and the Consultant agrees to perform the Services on the terms and conditions set forth herein.   Except as otherwise provided in Exhibit A, Consultant will have exclusive control over the manner and means of performing the Services, including the choice of place and time.  Consultant will provide, at Consultant’s own expense, a place of work and all equipment, tools and other materials necessary to complete the Services.  

1.2     Location.  The Services shall be performed at such place or places and at such time or times as Travere and Consultant shall reasonably agree.

1.3    Information Technology and Training.  Depending on the Services Consultant performs, Consultant may have access to Travere’s telecommunications, networking and/or information processing systems (the “Systems”), including, for example, the ability to create, access and use stored computer files, email messages and voice messages. In connection therewith, Consultant agrees: (i) Consultant has no expectation of privacy with respect to the Systems, and Consultant’s activities involving the Systems may be monitored and the contents of Consultant’s files and messages therein may be reviewed and disclosed by Travere at any time without notice to Consultant, (ii) Consultant will not give to any other person any user names or passwords applicable to Consultant’s access to the Systems unless authorized in writing by the sponsoring Travere manager or authorized personnel from Travere’s IT department, (iii) Consultant will not seek to obtain another person’s user names or passwords, and if obtained, Consultant will inform such person so that the passwords may be changed, (iv) Consultant will not attempt to access or possess any Travere information that Consultant is not authorized to access; (v) Consultant will not copy, distribute or reveal the contents of any software, software or system documentation or user manuals accessed in connection with the Services, (vi) Consultant will safeguard and maintain the security of all equipment assigned to Consultant by Travere, and will not introduce unauthorized software to the equipment or Systems, (vii) Consultant will not access Travere facilities for which Consultant is not authorized, (viii) 
1

Consultant will abide by all Travere policies, procedures and standards of which Consultant is informed, and during the term of this Agreement will promptly complete all Travere training as requested by Travere.

ARTICLE TWO
COMPENSATION

2.1    Compensation.   Unless this Agreement is terminated early in accordance with Section 7.2, in consideration of the Consultant’s performance of the Services, (i) for the period from January 1, 2022 through May 31, 2022 (the “Retainer Consulting Period”), Travere will pay to the Consultant a gross monthly retainer equal to $28,815, payable by the fifteenth day of each such month; and (ii) for the period from June 1, 2022 through December 31, 2022 (the “Hourly Consulting Period”), Travere will pay to the Consultant Four Hundred dollars ($400) per hour devoted by the Consultant to the performance of the Services.

2.2    Invoicing.  For services provided during the Hourly Consulting Period, Consultant will provide Travere with monthly invoices for the performance of Services hereunder. Invoices shall be sent to Travere accounts payable (AP@Travere.com) and reference the applicable Travere purchase order number and will set forth the actual number of hours worked and will itemize the Services provided.  Payments will be made by Travere within thirty (30) days of receipt. The account and payment currency of this Agreement is the US Dollar.

2.3    Equity.  Consultant’s consulting relationship with Travere under this Agreement immediately follows Consultant’s employment relationship with no break in service and therefore constitutes “Continuous Service” as defined in Travere’s 2018 Equity Incentive Plan, as amended.  As such, the Travere equity grants held by Consultant will have continued exercisability in accordance with their terms unless amended as set forth below in this Section 2.3.  Notwithstanding the existence of Continuous Service, Consultant hereby agrees that  none of his equity grants that were granted in connection with Consultant’s employment with Travere will continue to vest beyond December 31, 2021 other than the acceleration provided for in the Transition Agreement between Travere and Consultant dated October 12, 2021 (the “Transition Agreement”).  Effective and contingent on the Consultant providing Services through the Consulting End Date (as defined below), or upon any termination of this Agreement by Travere other than for Consultant’s material breach of this Agreement, subject to Section 2.5, the post-termination exercise period during which Consultant may exercise Consultant’s vested stock options following the  Consulting End Date or such termination, as applicable (which, under the terms of such options, would be three months following the Consulting End Date or such termination, as applicable) shall be extended to June 30, 2023, subject to earlier termination in the event of a change in control or corporate transaction as set forth in the terms of the equity incentive plan under which the equity awards were granted. Except to the extent provided in this Section 2.3, the Consultant’s stock options will continue to be subject to the terms and conditions of the equity plans and stock option grant notices and agreements pursuant to, or under, which they were granted.

2.4    NDA Filing Bonus.  Subject to Section 2.5, provided that Consultant is diligently performing the Services in accordance with this Agreement on such date, in the event of the Company’s receipt of the first Day 74 letter for sparsentan from the FDA confirming acceptance for filing of a New Drug Application (“NDA”), the Company shall pay Consultant an NDA Filing Bonus in the amount of $230,514 within 30 days following such receipt.

2.5    Release.  Consultant’s receipt of the post-termination exercise period extension pursuant to Section 2.3 and the bonus payable to Consultant pursuant to Section 2.4 shall each be subject to the requirement that Consultant execute and return to the Company a new Subsequent Release (as defined in the Transition Agreement).

2

2.6.Transition Agreement Amendment.  Upon execution of this Agreement and effectiveness of the Subsequent Release (as defined in the Transition Agreement), Section 7 of the Transition Agreement shall be, and hereby is, amended such that a new subsection (iii) is added as follows:  “and (iii)  Section 6.8(a) of the Employment Agreement shall be, and hereby is, amended such that the reference to “three (3) months” is replaced with “six (6) months”, and for purposes of Section 6.8 (a) of the Employment Agreement, Employee’s employment with the Company is deemed to be terminated without Cause as of December 31, 2021.

ARTICLE THREE
WARRANTIES AND COVENANTS

3.1    Consultant’s Warranties.  The Consultant represents and warrants:

a)Consultant has not entered into any agreement, whether written or oral, in conflict with this Agreement; 

b)Consultant has the full power and authority to enter into and perform this Agreement, including without limitation the right and unrestricted ability to assign ownership of the Travere Intellectual Property to Travere or its designee as set forth in Article Five;

c)Consultant’s performances hereunder will not result in the breach of any contract, arrangement or understanding Consultant may have with any third party or any policies or procedures of such third parties, including without limitation any academic institution. Consultant shall be solely responsible for, and agrees to obtain any necessary consent(s) from any third party, in advance of commencing the Services;

d)Consultant is not and has not been under investigation by the United States Food and Drug Administration (FDA) for debarment action and is not presently debarred pursuant to the Generic Drug Enforcement Act of 1992.  Consultant shall notify Travere immediately upon any inquiry or the commencement of any such investigation or proceeding.

3.2    Consultant’s Covenants.  Consultant:

a)shall act as an independent contractor with no authority to obligate Travere by contract or otherwise and not as an employee or officer of Travere; 

b)will not utilize the confidential information, funds, personnel, space, equipment or facilities of any third party while performing services for Travere;  

c)shall exercise only such powers and perform such duties as may from time to time be vested in Consultant or assigned to Consultant by Travere;

d)shall perform the Services and promote the interests of Travere to the best of Consultant’s skill and ability and in a professional manner;

e)shall not, during the term of this Agreement, directly or indirectly assist or provide services with respect to any program that is competitive or potentially competitive with the sparsentan or pegtibatinase programs; 

f)shall comply with all standards of safety, take due regard and comply with the safety regulations of Travere and all statutory provisions in effect, and report to Travere any incident which could give rise to unsafe working conditions or practices;

3

g)shall not assign or subcontract performance of this Agreement or any of the Services to any person, firm, company or organization without Travere’s prior written consent; 

h)shall not, during the term of this Agreement or for two years following its expiration or termination, recruit, solicit or induce any Travere employee, client, customer or account to terminate their employment or relationship with Travere;

i)shall comply with all applicable state, federal and local laws, rules and regulations with respect to performance of services hereunder; and

j)shall not initiate or participate in any communications with the United States Food and Drug Administration, other governmental agency or foreign equivalent concerning Travere or any of its programs unless required by law or requested to do so by Travere, and then, only upon prior consultation with Travere.

ARTICLE FOUR
CONFIDENTIAL INFORMATION

4.1    Confidentiality.  “Travere Confidential Information” shall mean all information disclosed to Consultant by or on behalf of Travere or its affiliates, or developed or observed by Consultant in the performance of Services. Consultant shall keep all Travere Confidential Information confidential and use such information only for the performance of the Services. Such Travere Confidential Information includes, but is not limited to, confidential or proprietary information, data (both technical and non-technical), materials and know-how. For clarity, nothing in this Agreement shall be deemed to modify or limit Consultant’s ongoing confidentiality obligations owed to Travere pursuant to Consultant’s employee confidentiality agreement dated July 26, 2018. 

Consultant shall have no obligation of confidentiality and non-use with respect to any portion of Travere Confidential Information which (i) is or later becomes generally available to the public through no act or omission of Consultant; or (ii) is obtained without restriction from a third party (other than an affiliate, consultant or collaborator of Travere) who had the legal right to disclose the information to Consultant. 

4.2    Authorized Disclosure.  Notwithstanding the provisions of Section 4.1, Consultant may disclose the Confidential Information without violating its obligations under this Agreement to the extent the disclosure is required by a valid order of a court or other governmental body of competent jurisdiction or is otherwise required by law or regulation; provided that, to the extent permitted, Consultant gives reasonable prior written notice to Travere of such required disclosure and, at Travere’s request and expense, cooperates with Travere’s efforts to contest such requirement, obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law or regulation required, or obtain other confidential treatment of such Confidential Information.

4.3    Return of Information.  Upon the termination of this Agreement, Consultant will promptly return to Travere all materials, records, documents, and other Travere Confidential Information in tangible form. Consultant shall retain no copies of such materials and information and, if requested by Travere, will delete all Travere Confidential Information stored in any magnetic, optical disc or other electronic memory.

4.4    Third Party Information.  Consultant acknowledges that Travere has received, and in the future will receive from third parties, confidential or proprietary information (“Third Party Information”) subject to a duty on Travere’s part to maintain the confidentiality of such information and to use it only for certain limited purposes.  During the term of this Agreement and thereafter, Consultant shall hold Third Party Information in the strictest confidence and shall not disclose or use Third Party Information, except the extent such disclosure or use is expressly authorized in writing by Travere.  In addition, Consultant shall 
4

not, in connection with the Services to be performed under this Agreement, disclose to Travere or utilize any information which is confidential or proprietary to Consultant or any third party.

4.6    Trading in Securities.  Consultant, by virtue of the Services provided hereunder, may have access to data and information which is material non-public information about a publicly listed company. United States securities laws prohibit any person who is given access to material, non-public information concerning a company from purchasing or selling securities in such company or from communicating the information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. 

4.7    Personal Data.  Depending on the Services Consultant performs, Consultant may be required to collect, retain, process, or disclose personal data, as defined in the General Data Protection Regulation (EU) 2016/679, and/or individually identifiable health information, as defined in the Health Insurance Portability and Accountability Act of 1996 (“IIHI”) (such personal data and IIHI, collectively, “Personal Data”).  In that event, Consultant shall abide by all applicable data protection and privacy laws when performing the Services and shall afford Personal Data all the protections afforded to Confidential Information as set forth in this Agreement.  Consultant shall adopt technical and organizational measures appropriate to prevent any unauthorized or accidental use, access, or processing of Personal Data, promptly inform Travere of any unauthorized access to or disclosure of Personal Data (a “Security Breach”), and provide Travere with all reasonable assistance to remedy any Security Breach.  Where applicable data protection laws require the parties to enter into additional agreements or undertakings, including international data transfer agreements, Consultant will undertake to ensure that all necessary agreements are implemented and in place.  Without limiting the generality of the foregoing, if Travere concludes that the Services to be performed hereunder necessitate that the parties enter into Standard Contractual Clauses (SCCs) in order to ensure compliance with the applicable data protection regulations, Consultant and Travere hereby agree to promptly enter into the appropriate form of SCC. 

4.8    Individually Identifiable Health Information.  Consultant shall treat any IIHI received under this Agreement confidentially and shall disclose such IIHI only to those who have the need to know the IIHI in connection with the performance of the Services, use and disclose IIHI only as required by law or in connection with the performance of the Services, implement reasonable safeguards to protect confidentiality, integrity, and availability of the IIHI, and notify Travere of any instances of which Consultant becomes aware in which the confidentiality of the IIHI has been breached.

ARTICLE FIVE
INTELLECTUAL PROPERTY

5.1    Ownership.  All information, results, data, and products arising from the performance of the Services (either solely by Consultant or jointly with others), or which result to any extent from the use of Travere’s property, including, without limitation, every invention, discovery, improvement, innovation, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material, pharmaceutical and method, whether or not patentable or copyrightable (collectively, “Travere Intellectual Property”) shall be the sole and exclusive property of Travere. Consultant shall promptly disclose to Travere all Travere Intellectual Property arising or resulting from the Services.

5.2     Assignment.  Consultant hereby assigns, transfers and conveys to Travere or its designee all of Consultant’s right, title and interest in Travere Intellectual Property. Consultant will, and will cause those persons who, with Travere’s knowledge and consent, are responsible for performing the Services to, execute and deliver any and all instruments and documents and take such other acts as may be necessary or desirable to document such transfer or to enable Travere or its designee to apply for, prosecute and enforce patents, trademark registrations or copyrights in any jurisdiction with respect to any Travere Intellectual Property, or to obtain any extension, validation, re-issue, continuation or renewal of any such 
5

intellectual property right.  Consultant irrevocably appoints Travere and its duly authorized officers and agents as Consultant’s agent and attorney for such purpose, which appointment is coupled with an interest. 
 

ARTICLE SIX
RELATIONSHIP OF THE PARTIES

6.1    Relationship.  The relationship of Consultant to Travere will be one of independent contractor and at no time will Consultant hold itself out to be an employee of Travere or represent itself, either directly or indirectly, as being connected with or interested in the business of Travere.

6.2    No Withholding.  No amount will be deducted or withheld from Travere’s payments hereunder to Consultant for state, federal or local taxes. No FICA, FUTA, SDI or state unemployment taxes will be payable by Travere on Consultant’s behalf and Consultant will be solely responsible for and will pay such taxes.

6.3    Tax.  Consultant will be responsible for making appropriate filings and payments to the federal, state and local taxing authorities, including payments of all withholding and payroll taxes due on compensation received hereunder, estimated income payments, employment and self-employment taxes, if applicable.

6.4    Worker’s Compensation.  Consultant acknowledges that if Consultant is injured while performing work for Travere hereunder, Consultant will not be covered for such injury under Travere's insurance policies, including under any Worker's Compensation coverage provided for Travere's employees, and further acknowledges that Consultant is solely responsible for providing Worker's Compensation insurance. 

ARTICLE SEVEN
TERM AND TERMINATION

7.1    Term.  This Agreement shall terminate on December 31, 2022 (the “Consulting End Date”) unless earlier terminated as set forth below.

7.2    Termination.  This Agreement may be terminated (a) by Travere in its sole discretion (i) at any time following the Retainer Consulting Period, upon 30 days’ prior written notice to Consultant, or (ii) at any time during the term of this Agreement, immediately upon written notice to Consultant upon Consultant’s material breach of this Agreement and (b) by Consultant in its sole discretion (i) upon 30 days’ prior written notice to Travere or (ii) immediately upon written notice to Travere upon Travere’s material breach of this Agreement. Termination of this Agreement shall not relieve either party of any liability or obligation that, at the time of such termination, has already accrued.    

7.3    Effect of Termination.  Upon the termination of this Agreement, each party shall be released from all obligations and liabilities hereunder except those arising under Section 2.3, Articles Four, Five and Eight, and Sections 6.2, 6.3 and 7.3. 

ARTICLE EIGHT
MISCELLANEOUS

8.1    Waiver.  None of the terms of this Agreement may be waived except by an express agreement in writing signed by the party against whom enforcement of such waiver is sought. The failure or delay of either party in enforcing any of its rights under this Agreement shall not be deemed a continuing waiver of such right.  

6

8.2    Mutual Non-Disparagement.  Consultant agrees that he will not disparage the Company or its affiliates or its or their products, programs, directors, officers, successors or assigns, with any written or oral statement.  The Company agrees to instruct its current directors and executive officers to not disparage Consultant with any written or oral statement.  Nothing in this paragraph shall prohibit the parties from providing truthful information in response to a subpoena or other legal process.
8.3    Entire Agreement.  This Agreement and the Transition Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings among the parties (whether written or oral) relating to said subject matter.

8.4    Amendments.  This Agreement may not be released, discharged, amended or modified in any manner except by an instrument in writing signed by Consultant and a duly authorized officer of Travere.

8.5    Assignment.  Travere has specifically contracted for the Services of Consultant and, therefore, Consultant may not assign or delegate Consultant's obligations under this Agreement, either in whole or in part, without the prior written consent of Travere. Travere may assign this Agreement at any time without the prior consent of Consultant.

8.6    Severability.  If any provision of this Agreement is, becomes, or is deemed invalid, illegal or unenforceable in any jurisdiction, such provision shall be deemed amended to conform to the applicable laws so as to be valid and enforceable, or, if it cannot be so amended without materially altering the intention of the parties hereto, it shall be stricken and the remainder of this Agreement shall remain in full force and effect.

8.7    Headings.  Article and Section headings contained in the Agreement are included for convenience only and are not to be used in construing or interpreting this Agreement.

8.8    Counterparts.   This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000), or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Agreement and all matters related thereto, with such electronic signatures having the same legal effect as original signatures. The parties agree that this Agreement may be electronically signed.

8.9    Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the state of California, without regard to choice of law principles.  Consultant’s obligations under this Agreement are of a unique character that gives them particular value; breach of the obligations may result in irreparable harm and continuing damage to Travere for which there may be no adequate remedy at law.  In the event of such a breach, Travere shall be entitled to seek injunctive relief and/or a decree for specific performance, and such other and further relief as may be proper, without prejudice to any other rights and remedies for a breach of this Agreement.

8.10    Public Announcements.  Except as may be required for Travere to comply with applicable disclosure requirements, Neither party shall make any press release, statement or public announcement that mentions or refers to the other without the other parties’ prior written consent.

8.11     Notices.  Any notice required or otherwise made pursuant to this Agreement shall be in writing, personally delivered or sent by certified mail, return receipt requested, or recognized courier service, properly addressed. Notices shall be deemed effective on the date received if personally delivered or sent by certified mail or recognized courier.

7

If to CONSULTANT, address to:

Noah Rosenberg, M.D.

If to TRAVERE, address to:  

Travere Therapeutics, Inc.
ATTN: Legal Dept.
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130

[SIGNATURE PAGE TO FOLLOW]

8

IN WITNESS WHEREOF, the parties have entered into this Agreement on the date first above written.

TRAVERE THERAPEUTICS, INC.     

/s/ Eric Dube
By: Eric Dube, Ph.D.
Title: President and CEO

CONSULTANT

/s/ Noah Rosenberg
Noah Rosenberg, M.D.

9

EXHIBIT A
Description of Consulting Services

1.Scope of Services (detailed description of Services to be performed):

In coordination with the Chief Executive Officer (CEO); the Chief Medical Officer; the SVP, Research and Development and/or the VP, Pharmacovigilance of Travere, or such other individuals designated by the CEO, Consultant will:

a)provide support with respect to regulatory submissions and related activities; 
b)provide transitional consulting services to Travere; and 
c)perform such additional Services as mutually agreed upon by the parties.

It is understood and agreed that Consultant may provide such Services on a remote-basis and further that Consultant may be unavailable while away on vacation for up to two (2) weeks during the Retainer Consulting Period. 

2.Deliverables/Timelines/Payment Terms:  
															
	Services to be Performed	Deliverable(s)	Due Date/
Timeline
	Payment Terms	Total
	Per Scope of Services above.	Per Travere’s request.	Per Travere’s request.	

a) $28,815 per month during Retainer Consulting Period;

b) Hourly rate is $400 per hour during Hourly Consulting Period
	
			Travel and out of pocket expenses	With prior approval
			Total Compensation 
(not to exceed)
	$

3.Other Payment Terms:
a)Invoices and payment to be issued in US Dollars.  
b)Invoices must be submitted with all requests for payment. 
c)Copies of receipts must be provided with invoices for reimbursement of travel and out of pocket expenses.
d)Invoices will be sent to Accounts Payable and reference the Purchase Order Number.  The period of work covered by each invoice shall not be more than one month and all work performed in any calendar month shall be invoiced within twenty-one (21) days of each month end.
e)Payment will be made by Travere within thirty (30) days of Travere’s receipt of the corresponding invoice.
f)Payments shall be made by check to Consultant.

10

						
	Invoices shall be sent to:
	Checks shall be made payable to:

	Travere Therapeutics, Inc. 
Attn: Accounts Payable
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
Email: AP@Travere.com
	Noah Rosenberg, M.D.
 
 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]